Literature DB >> 26117365

Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate.

Maude Beaudoin-Gobert1, Justine Epinat1, Elise Météreau1, Sandra Duperrier1, Sara Neumane1, Bénédicte Ballanger1, Franck Lavenne2, François Liger2, Christian Tourvielle2, Frédéric Bonnefoi2, Nicolas Costes2, Didier Le Bars3, Emmanuel Broussolle4, Stéphane Thobois5, Léon Tremblay1, Véronique Sgambato-Faure6.   

Abstract

Serotonergic (5-HT) neurons degenerate in Parkinson's disease. To determine the role of this 5-HT injury-besides the dopaminergic one in the parkinsonian symptomatology-we developed a new monkey model exhibiting a double dopaminergic/serotonergic lesion by sequentially using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 3,4-methylenedioxy-N-methamphetamine (MDMA, better known as ecstasy). By positron emission tomography imaging and immunohistochemistry, we demonstrated that MDMA injured 5-HT nerve terminals in the brain of MPTP monkeys. Unexpectedly, this injury had no impact on tremor or on bradykinesia, but altered rigidity. It abolished the l-DOPA-induced dyskinesia and neuropsychiatric-like behaviours, without altering the anti-parkinsonian response. These data demonstrate that 5-HT fibres play a critical role in the expression of both motor and non-motor symptoms in Parkinson's disease, and highlight that an imbalance between the 5-HT and dopaminergic innervating systems is involved in specific basal ganglia territories for different symptoms.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Parkinson’s disease; dyskinesia; monkey; neuropsychiatric symptoms; serotonin

Mesh:

Substances:

Year:  2015        PMID: 26117365     DOI: 10.1093/brain/awv183

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  23 in total

1.  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Authors:  Shawn P Alter; Kristen A Stout; Kelly M Lohr; Tonya N Taylor; Kennie R Shepherd; Minzheng Wang; Thomas S Guillot; Gary W Miller
Journal:  Exp Neurol       Date:  2015-09-30       Impact factor: 5.330

Review 2.  Molecular imaging and neural networks in impulse control disorders in Parkinson's disease.

Authors:  I Aracil-Bolaños; A P Strafella
Journal:  Parkinsonism Relat Disord       Date:  2015-08-12       Impact factor: 4.891

Review 3.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

Review 4.  The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective.

Authors:  Manolo Carta; Anders Björklund
Journal:  J Neural Transm (Vienna)       Date:  2018-02-26       Impact factor: 3.575

Review 5.  Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.

Authors:  Véronique Sgambato; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2018-03-03       Impact factor: 3.575

Review 6.  Dopamine and serotonin modulation of motor and non-motor functions of the non-human primate striato-pallidal circuits in normal and pathological states.

Authors:  Véronique Sgambato-Faure; Léon Tremblay
Journal:  J Neural Transm (Vienna)       Date:  2017-02-07       Impact factor: 3.575

7.  Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Allison Weinkle; Stella M Papa; Yoland Smith
Journal:  Cereb Cortex       Date:  2022-04-20       Impact factor: 4.861

8.  Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice.

Authors:  Yukiko Ochiai; Masayo Fujita; Yoko Hagino; Kazuto Kobayashi; Ryoichi Okiyama; Kazushi Takahashi; Kazutaka Ikeda
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 9.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

10.  Imaging Dopamine and Serotonin Systems on MPTP Monkeys: A Longitudinal PET Investigation of Compensatory Mechanisms.

Authors:  Benedicte Ballanger; Maude Beaudoin-Gobert; Sara Neumane; Justine Epinat; Elise Metereau; Sandra Duperrier; Emmanuel Broussolle; Stephane Thobois; Frederic Bonnefoi; Christian Tourvielle; Franck Lavenne; Nicolas Costes; Didier Lebars; Luc Zimmer; Véronique Sgambato-Faure; Léon Tremblay
Journal:  J Neurosci       Date:  2016-02-03       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.